Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521145 | 1.00 | PTGER1 (0.41) | PTGER1MAOBGSK3BBACE1KDM5A | |
| SCHEMBL4465621 | 0.82 | MAOB (0.46) | PTGER1MAOBGSK3BBACE1ALKBH1 | |
| SCHEMBL4465611 | 0.82 | MAOB (0.46) | PTGER1MAOBGSK3BBACE1ALKBH1 | |
| SCHEMBL3521852 | 0.82 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL3521858 | 0.82 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL3520089 | 0.79 | MAPK14 (0.51) | PTGER1MAOBKDM5AKDM4CKDM5B | |
| SCHEMBL3523048 | 0.78 | MAPK14 (0.39) | PTGER1MAOBMAPK14 | |
| SCHEMBL3519136 | 0.76 | MAPK14 (0.49) | MAOBMAPK14 | |
| SCHEMBL4392632 | 0.75 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL4389770 | 0.75 | MAPK14 (0.62) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | PTGER1 245/4885MAOB 1718/4885GSK3B 2265/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | PTGER1 215/4885MAOB 1814/4885GSK3B 2162/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | PTGER1 245/4885MAOB 1718/4885GSK3B 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.